Ephraim J Fuchs

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6630733/publications.pdf

Version: 2024-02-01

51 papers	5,935 citations	147801 31 h-index	197818 49 g-index
52 all docs	52 docs citations	52 times ranked	4363 citing authors

#	Article	IF	Citations
1	Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 260-269.	0.4	4
2	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood, 2022, 139, 1452-1468.	1.4	52
3	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. Transplantation and Cellular Therapy, 2022, 28, 109.e1-109.e8.	1.2	12
4	Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. Transplantation and Cellular Therapy, 2022, 28, 259.e1-259.e11.	1.2	11
5	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. Transplantation and Cellular Therapy, 2022, 28, 406.e1-406.e6.	1.2	4
6	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood, 2021, 137, 420-428.	1.4	119
7	Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients. Transplantation and Cellular Therapy, 2021, 27, 879.e1-879.e3.	1.2	0
8	Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 863.e1-863.e5.	1.2	4
9	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
10	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Advances, 2020, 4, 3913-3925.	5.2	52
11	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematology,the, 2019, 6, e183-e193.	4.6	111
12	Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2019, 25, 1128-1135.	2.0	38
13	Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. Seminars in Hematology, 2019, 56, 183-189.	3.4	8
14	Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1022-1028.	2.0	29
15	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Nonâ€“First-Degree Related Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1099-1102.	2.0	61
16	Human papilloma virusâ€“specific T cells can be generated from naÃ¯ve T cells for use as an immunotherapeutic strategy for immunocompromised patients. Cytotherapy, 2018, 20, 385-393.	0.7	15
17	Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 126-136.	3.9	33
18	Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 343-352.	2.0	61

#	Article	IF	Citations
19	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Advances, 2018, 2, 299-307.	5.2	69
20	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. Blood Advances, 2018, 2, 1180-1186.	5.2	35
21	Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 2056-2064.	2.0	32
22	Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2017, 23, 612-617.	2.0	17
23	Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica, 2017, 102, 391-400.	3.5	152
24	Haplotype Counting for Sensitive Chimerism Testing. Journal of Molecular Diagnostics, 2017, 19, 427-436.	2.8	10
25	Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood, 2017, 129, 1389-1393.	1.4	69
26	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 2127-2136.	2.0	17
27	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2017, 23, 310-317.	2.0	50
28	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 325-332.	2.0	61
29	Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Advances, 2017, 1, 288-292.	5.2	84
30	Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Advances, 2017, 1, 397-400.	5.2	30
31	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
32	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. Journal of Hematology and Oncology, 2016, 9, 35.	17.0	78
33	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. Journal of Clinical Oncology, 2016, 34, 3141-3149.	1.6	212
34	Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Seminars in Hematology, 2016, 53, 90-97.	3.4	118
35	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigenâ€“Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 112-118.	2.0	37
36	Modern approaches to HLA-haploidentical blood or marrow transplantation. Nature Reviews Clinical Oncology, 2016, 13, 10-24.	27.6	262

#	Article	IF	Citations
37	Shortened-Duration Tacrolimus after Nonmyeloablative HLA-Haploidentical (NMA haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Facilitates Strategies for Relapse Reduction. Blood, 2016, 128, 831-831.	1.4	3
38	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood, 2015, 125, 3024-3031.	1.4	259
39	Haplo graft engineering: sculpting to a T. Blood, 2015, 125, 2315-2316.	1.4	1
40	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood, 2015, 126, 1033-1040.	1.4	565
41	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Science Translational Medicine, 2015, 7, 288ra78.	12.4	104
42	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biology of Blood and Marrow Transplantation, 2015, 21, 2115-2122.	2.0	26
43	Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 1485-1492.	2.0	43
44	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood, 2014, 124, 3817-3827.	1.4	165
45	Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy). Blood, 2014, 124, 730-730.	1.4	5
46	Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies. Biology of Blood and Marrow Transplantation, 2013, 19, 647-652.	2.0	113
47	5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 754-758.	2.0	58
48	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood, 2011, 118, 282-288.	1.4	549
49	Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 533-542.	2.0	168
50	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2008, 14, 641-650.	2.0	1,525
51	Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-ÎºB. Nature Cell Biology, 2001, 3, 409-416.	10.3	316